Diagnostic Precision

A SeraCare blog focused on precision medicine and advanced clinical diagnostics

Choose your Article Focus | NGS | Molecular & Serology

Design and Development of Compromised FFPE Reference Materials

Supporting High-Quality Testing for Women’s Health

Do COVID-19 infections affect NIPT?

Assessing RNA Extraction with FFPE Fusion RNA Reference Materials

Diagnostic Testing Schemes for NTRK Cancers: All Roads Lead to NGS

Evolution of non-invasive prenatal testing (NIPT) testing

Multi-Lab Study of Fusion RNA Reference Standards for Targeted NGS

What is Non-Invasive Prenatal Testing (NIPT)?

So Many Posters, So Little Time

Newly Published Multi-Laboratory Study Provides Utility and Validation of the Use of ctDNA Reference Standards

Making the Shift from Technological Innovation to Operational Excellence: Delivering on the Promise Of Next-Generation Sequencing for Personalized Medicine

Precision Medicine and Clinical Labs: AACR Dinner Seminar Recap

Presenting NTRK Reference Materials for Global Assay Standardization at AACR 2019

AACR 2019 Day Three: Understanding T-cell Therapy for Unique Cancer Mutations

AACR 2019 Day Two: Learning About the Microbiome in Immuno-Oncology

AACR 2019 Day One Highlights: Next-Generation Car T Cells

New Podcast: Target the Tumor Mutational Burden and Pursue Harmonization

Video: See How an EQA Improves Clinical Genomics Testing with Affordable Custom Reference Standards

Ground Control to Major Tom: Use Controls and Keep Your Assay Running On

The Full Authority Companion Diagnostic

Customer Data: Use of Seraseq ctDNA Reference Samples to Validate Detection of Low Frequency Variants in a cfDNA-based NGS Lung Cancer Panel

NTRK Fusion Testing for New Therapies

Keys to Better Liquid Biopsy Assay Sensitivity – AMP Corporate Workshop Video

Tips for Better EGFR Mutation Testing

Workshop Video: Two Experts Take on Clinical Genomics QC and Standardization at AMP

Two Must-See Liquid Biopsy Poster Videos From AMP 2018

Building and Implementing Liquid Biopsy Assays with the Industry’s Most Patient-Like Reference Materials

To Realize the Potential of Liquid Biopsies, Focus on Higher Quality Research and Clinical Data Sets

Keep Calm and Standardize On

As Immunotherapy Use Rises, Critical Gaps Remain in Harmonizing Tumor Mutational Burden Measurements

cccDNA and HBV:  New Testing Methods May Allow for Earlier, Non-Invasive Detection of Hepatocellular Carcinoma

If I Call Out of Tune, Would Mutations Stand Up and Walk Out on Me?

Microsatellite Instability Testing to Predict Immunotherapeutic Response: New Tools to Meet Testing Challenges

A First of its Kind Survey to Assess the QC Habits of Labs Running Clinical NGS Assays

Developing a Rock-Solid Lung Cancer Assay, Part 2

Ebola Outbreak 2018: Diagnostics Again are Essential to Minimize Spread and to Control Disease

How A New Generation of ctDNA Reference Standards Are Enabling the Promise of Precision Medicine

FAQ: What to do when your NGS assay fails to detect a variant contained in Seraseq Reference Materials?

Sensitive ctDNA Assays are Required for Minimal Residual Cancer Detection

Twists and Turns That Lead From “Curiosity Driven Research” To Innovative Diagnostics

Developing a Rock-Solid Lung Cancer Assay

An Efficient and Ultrasensitive NGS Solution for Profiling ctDNA [Poster Talk Video]

CNVs and Tumor Profiling: New CNV Materials for Breast, Lung, and Brain Cancer

Reliable Interpretation of NGS Data: New Poster Talk Video

With so many options, how do you select the best NGS cancer assay?

How am I going to test my assay? Should I use patient samples or biosynthetic materials?

AMP Reference Material Forum: Themes and Highlights

Higher Quality for Better QC

As to Myeloid Diseases, Make a Habit of Three Things

3 Steps for Building a Bulletproof Clinical NGS Assay: Step 3

AMP 2017 Highlights: The Epigenetic Basis of Common Human Disease

3 Steps for Building a Bulletproof Clinical NGS Assay: Step 2

The First Comprehensive Myeloid Cancer Reference Materials for NGS Assays

3 Steps for Building a Bulletproof Clinical NGS Assay: Step 1

Clinical NGS Assay Developers: Eliminate Your Specimen Search Headaches

A New Focus on Implementing Clinical Genomics

This is the Number One Risk to Your Clinical Sequencing Assay

Is Your NGS-Based Assay on the Right TRK?

Expert opinions on LDT transparency and standardization

You can’t validate everything… can you?

Rapid and Early detection of Listeria to prevent food poisoning

Accelerating Liquid Biopsy Assay Development

Does your NGS lab struggle with quality control? [Free Guide]

Three liquid biopsy problems solved by the most patient-like ctDNA reference materials

What specifically contributes to high levels of NGS accuracy?

Dr. Andrea Ferreira-Gonzalez on the Seven Benefits of Clinical Genomics Universal Standardization

How Many Target Copies Are Present in Your Plasma DNA Sample?

Real-World Needs for Genetic Testing Reference Materials

How to Validate Your Lab’s Clinical Genomics Tests Affordably … and Revalidate

Improve the Reliability of Your Zika Diagnostic Assays

Futureproof Your Clinical Genomics Lab’s Compliance: 3 Tips to Prepare for Potential Requirements

3 Tips for Reducing the Costs of Running Your Clinical Genomics Lab (While Maintaining Accuracy and Efficiency)

Your Lab Is Growing; Here’s How to Train Your New Staff Quickly

Prevent Assay Drift In Your Clinical NGS Assay by Avoiding 2 Common Mistakes

3 Root Causes of Downtime for Clinical Genomic Testing Labs (and How to Recover Fast)

Extracting Formalin-fixed, paraffin-embedded (FFPE) nucleic acids for NGS

Highlights from the Precision Medicine World Congress

Introducing A New Reference Material for KRAS Molecular Testing

Multiplexed Reference Materials as Controls for Cardiomyopathy Diagnostic Next-Generation Sequencing

Clinical Laboratories: You Are Not Alone. (Part II)

Clinical Laboratories: You Are Not Alone.

Reference Materials for Your Unique Reproducibility Needs

What lessons for liquid biopsy have been learned from fetal aneuploidy testing?

FDA-AACR Liquid Biopsies in Oncology Drug and Device Workshop

IVD Guidance for NGS Manufacturers

Mary-Claire King at the European Society for Human Genetics 2016

SeraCare introduces AccuPlex™ Zika Reference Material

American Association for Cancer Research 2016 ctDNA highlights

Previewing the American Association for Cancer Research 2016 Conference #AACR16

The FDA NGS-based Oncology Panels Workshop

Circulating Tumor DNA Reference Materials

Highlights from the 2016 Molecular Medicine Tri-Conference

Molecular Tri-Conference Preview (San Francisco CA March 7-11 2016)

Oncology Regulatory Framework for NGS Webinar Friday Feb 26 2016

Circulating Tumor DNA Poster at Keystone Symposium

Does synthetic DNA sequence behave the same as cell-line DNA?

Analytical Validation using Biosynthetic Mutation Targets

LDT Oversight Counterpoint: Tempering FDA Arguments

Newsworthy Science in 2015

LDT Oversight: Why the FDA makes a point

Sanger versus Next-Generation Sequencing Infographic

The current state of non-invasive prenatal testing

Video Interview: Developing Aneuploidy Reference Materials

What is Non-Invasive Prenatal Testing (NIPT)?

Association for Molecular Pathology 2015 Conference Highlights

Posters from AMP 2015 Available for Download

Circulating tumor DNA liquid biopsy needs reference standards

Association of Molecular Pathology Meeting Nov 4-7 2015

Video: What are the sources of variability in FFPE material?

Genetic Profiling of Pediatric Oncology Patients

Precision Medicine Perspective

What is Precision Medicine?

Video Interview: Why use reference materials for precision medicine?

Introducing SeraCare’s Genomic Precision Blog